S-1: Adagio Medical Holdings Files for Resale of Up to 67.9 Million Shares of Common Stock

Adagio Medical Holdings seeks to register the resale of up to 67.9 million common shares by existing stockholders, including shares from PIPE investors, convertible noteholders, and the Sponsor.

Summary

• Adagio Medical Holdings has filed a registration statement for the potential resale of up to 67,963,695 shares of its common stock by selling stockholders.
• The shares include 7,951,913 PIPE Shares and 110,000 Registration Delay Shares, 670,000 Pre-Funded Warrant Shares, and 7,528,727 PIPE Warrant Shares.
• Additionally, the offering includes 46,717,980 Convertible Note Shares, 900,000 Convert Warrant Shares, and 2,354,100 shares issued to the Sponsor.
• The selling stockholders may offer these shares publicly or through private transactions at prevailing market or negotiated prices.
• Adagio Medical will not receive any proceeds from the sale of these shares, except for potential cash received upon the exercise of warrants.
• The company believes the likelihood of warrant holders exercising their warrants for cash is dependent on the trading price of their common stock.
• The company will bear the costs of registration, while selling stockholders will cover commissions and discounts.
• The shares being offered represent a substantial percentage of the total outstanding shares, which could lead to a decline in the market price.
• Lock-up restrictions for some shareholders will expire on January 31, 2025, potentially leading to further sales.
• Despite a decline in the stock price, some selling stockholders may still profit due to lower purchase prices.
• The company's common stock is listed on The Nasdaq Capital Market under the symbol ADGM, with a last reported sales price of $1.00 per share on January 9, 2025.
• Adagio Medical is an emerging growth company and has elected to comply with reduced public company reporting requirements.

Sentiment

Score: 4

Explanation: The document is primarily a registration statement, which is inherently neutral. However, the risks associated with the resale of a large number of shares and the potential for stock price decline contribute to a slightly negative outlook.

Positives

• The company will receive up to approximately $96.8 million from the exercise of the Warrants, assuming exercise in full of all the Warrants for cash.
• The company will bear all costs, expenses and fees in connection with the registration of these securities, including with regard to compliance with state securities or blue sky laws.

Negatives

• The sale of all the securities being offered in this prospectus, or the perception that these sales could occur, could result in a significant decline in the public trading price of our securities.
• The frequency of such sales could also cause the market price of our securities to decline or increase the volatility in the market price of our securities.
• The market price of our Common Stock is lower than the exercise prices of the Warrants as of the date of this prospectus.
• If the trading price for our Common Stock is less than the exercise price of the Warrants, meaning the Warrants are out of the money, we believe the holders of Warrants will be unlikely to exercise these Warrants.

Risks

• The shares of Common Stock being offered in this prospectus represent a substantial percentage of our outstanding Common Stock, and the sales of such shares, or the perception that these sales could occur, could cause the market price of our Common Stock to decline significantly.
• The future exercise of registration rights may adversely affect the market price of our Common Stock.
• The Perceptive PIPE Investor has control over key decision making as a result of its control of a majority of the voting power of our outstanding Common Stock.
• Our stock price may be volatile and may decline regardless of its operating performance.
• We may be unable to maintain the listing of our securities on Nasdaq in the future.
• Future sales of shares by existing stockholders could cause our stock price to decline.
• We may issue additional shares of common stock or other equity securities without your approval, which would dilute your ownership interests and may depress the market price of our common stock.
• We have identified material weaknesses in our internal controls over financial reporting. If we are unable to remediate these material weaknesses, if management identifies additional material weaknesses in the future or if we otherwise fail to maintain effective internal controls over financial reporting, we may not be able to accurately or timely report our financial position or results of operations, which may adversely affect our business and stock price or cause our access to the capital markets to be impaired.

Future Outlook

The company believes the likelihood that warrant holders will exercise their warrants for cash is dependent upon the trading price of their common stock.

Industry Context

The medical device industry is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities of industry participants.

Comparison to Industry Standards

• Competitors include Medtronic, Boston Scientific, Abbott and Johnson & Johnson.
• These companies have significantly greater market share and resources.
• The company competes on the basis that its products are designed to enable more physicians to treat more patients more efficiently and effectively.

Related Party Transactions

• The document discusses transactions with related parties, including the Sponsor and Perceptive Life Sciences Master Fund, Ltd, through subscription agreements and convertible security financing.

Stakeholder Impact

• The sale of shares by selling stockholders could result in a significant decline in the public trading price of our securities.
• The frequency of such sales could also cause the market price of our securities to decline or increase the volatility in the market price of our securities.

Next Steps

• The selling stockholders will determine when and how they will dispose of the shares of Common Stock registered for resale under this prospectus.

Key Dates

Keywords

common stock, registration statement, securities, warrants, Adagio Medical, PIPE, resale, convertible notes, stockholders